Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
From a long stint at the European Medicines Agency’s (EMA) Office of Therapies for Neurological and Psychiatric Disorders to her present-day practice as a clinical psychiatrist at leading cancer research hospital Gustave Roussy, Dr. Florence Butlen-Ducuing has had a front-row seat to the evolution of psychedelic research and drug development in Europe.
Explore our interactive database of psychedelic patent activity in August 2025 via our Pα+ interface.
Last Thursday, FDA published the complete response letter (CRL) it sent to Lykos Therapeutics last year, when it rejected its MDMA for PTSD new drug application. Here, we take a closer look at the three dealbreaking issues, speak with insiders and observers about its contents, and discuss what it might mean for Lykos’ road to resubmission.
Psychedelic CEOs’ FDA Wish-List • APA Division 56 President Jessica Punzo on Psychologists and Psychedelics • Compass’ Phase 2 PTSD Study Published • Cybin Ousts CEO Doug Drysdale • DoD to Test Military for Psilocybin • MindMed’s Phase 2b LSD for GAD Study Publishes • and more..
FDA has published its complete response letter (CRL) to Lykos Therapeutics, citing durability, safety, and bias concerns in rejecting MDMA therapy for PTSD. Here, we very briefly unpack the letter.
The FDA is pushing researchers to reduce their use of animal models and instead adopt ‘new approach methodologies’, like organoids and AI modelling. Here, Dr. Alaina Jaster speaks with psychedelic scientists and drug developers to unpack the debate.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
Archived versions of our Psychedelic News Feed.
This is an archived version of our Psychedelic News Feed, from January 5 – June 1, 2025
This is an archived version of our Psychedelic News Feed, from September 2 to December 29, 2024.
This is an archived version of our Psychedelic News Feed, from March 4, 2024 – September 1, 2024.
A special version of our Psychedelic News Feed to mark April 1st, 2024.
This is an archived version of our Psychedelic News Feed, from February 5 2024 – March 3 2024.
This is an archived version of our Psychedelic News Feed, from January 8 2024 – February 4 2024.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
